- The “Glioblastoma Multiforme (GBM) – Pipeline Insights 2018″ report covers an in-depth analysis of Glioblastoma Multiforme drug molecules currently undergoing clinical studies.
- It provides a deep understanding of potential Glioblastoma Multiforme drug molecules across all drug development phases.
- The report assesses the pipeline Glioblastoma Multiforme molecules by stage of development (discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration), by recruitment status (recruiting, active not recruiting, completed, NA, and unknown), therapy type (monotherapy, combination products) molecule type (small molecules, biologics) and route of administration (oral, IV, and others).
- The report provides a snapshot of discontinued and dormant drugs too. Also, the report includes critical insights on other development activities, including (but not limited to) – licensing, collaborations, acquisitions, funding, patent, and regulatory designations.
- The report covers company profiles key players in developing Glioblastoma Multiforme drug molecules. The company profile includes essential info on overview, financial highlights, product portfolio, business strategies, and key recent developments.
- Glioblastoma Multiforme (GBM), also known as glioblastoma, is a type of cancer which is aggressive and develops within the brain.
- It is considered as a rapidly-growing glioma, which is developed from star-shaped glial cells including oligodendrocytes and astrocytes that supports the nerve cells in the brain. GBM is also known as grade IV astrocytoma and is considered as the most invasive forms of the glial tumors.
- This is a fast-growing and aggressive form of the tumor in the central nervous system and will spread to the nearby brain tissues.
- The symptoms include seizures, vomiting, constant headaches, blurred or double vision, difficulty in speaking and also have similar symptoms like stroke showing poor blood flow to the brain that results in cell death. Worsening symptoms of GBM leads to unconsciousness.
- In addition, tuberous sclerosis, neurofibromatosis, Von-Hippel-Lindau disease, Turcot syndrome, and Li-Fraumeni syndrome are the genetic disorders that are caused by increasing incidences of gliomas.
- As there is no current treatment found to be available for GBM, the market growth is known to rise shortly. Giving high doses of steroid helps to reduce the symptoms of brain swelling. Supply of various types of steroids in the market has failed to increase the survival rate.
- The treatment options that do not increase the overall survival rate in the patients like surgical resection is followed by chemotherapy and radiotherapy, is another factor contributing towards the expected growth of the market.
Market Growth Analysis
- The pipeline of GBM is rich with a lot of therapeutic drugs and devices that are expected to receive FDA approval shortly for the clinical trials.
- Currently, the FDA approved drugs of GBM are temozolomide that includes Temodar, Temodal and Tomcat, bevacizumab that provides for Avastin and carmustine wafers are going to fuel the GBM market. Temozolomide is introduced by NICE as one of the options for newly diagnosed GBM treatment.
- Temozolomide accounts for the largest market share concerning the revenue due to the advantages offered by the drug that includes delayed progression without hampering the quality of life and less adverse effects of the molecule.
- Furthermore, methylated or alkylated DNA in the drugs structural anomalies provides a better therapeutic efficacy that will lead to the high preference of the drug among the other segments.
- On the other side, pipeline drugs under phase III trials including Rindopepimut (CDX-110) and DCVax are known to be the fast-growing segment over the forecast period as a result of observation of adverse events in adult patients with the use of the available drugs.
- Biologic products produce a unique opportunity for focal treatment of GBM that presents a practical and feasible treatment for the GBM patients which will contribute to the growth of the GBM market in the next few years.
Drivers & Restraints
- The habits of increasing alcohol consumption, increasing incidence of seizure and changing lifestyle are some of the drivers for the GBM market growth.
- Furthermore, the fact showing that glioma stem cells will resist conventional treatments raises urgent need for the alternative treatment therapies for GBM thus drives the market. Increasing of R&D in fields of gene therapy and molecular biotechnology for the treatment of CNS disorders and cancer is known to fuel the market growth across the forecast period.
- However, higher expenditure involved in the research employing genomics-based research is considered an essential restraint for the market.
The scope of the report
• Provides comprehensive understanding of active Glioblastoma Multiforme pipeline drug candidates
• Includes comprehensive pipeline product coverage with segregation by various stages of the pipeline from discovery to late-stage.
• Offers pipeline assessment by monotherapy, combination therapy products, and route of administration
• Provides a comparative analysis of key marketed products and pipeline drug candidates
• Includes detailed pipeline drug profiles covering – product description, chemical information, molecule type, mechanism of action, route of administration, product safety and efficacy, developers and collaborators
• Provides essential info on players involved in clinical R&D of Glioblastoma Multiforme drug candidates.
• Provides in-depth coverage of crucial news related to Glioblastoma Multiforme drug molecules, including significant mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates.
Reasons for purchasing this report:
• To obtain an understanding of the current Glioblastoma Multiforme pipeline landscape.
• To determine drug development dynamics and leverage it for innovation of novel or repositioned drugs.
• To valuably optimize R&D activities in-line with robust therapeutic drug markets.
• To devise strategic initiatives by identifying prospective partners with progressing projects.